An Update for NYS Healthcare Providers on COVID-19

February 11, 2021
Agenda

• Global, National, New York State Updates
• COVID-19 variants update
• Multi Inflammatory Syndrome in children, adults (MIS-C/MIS-A) update
• Long-Term Effects of COVID-19
• Indoor dining: Re-opening
• COVID-19 vaccine eligibility and updates
• COVID-19 vaccine safety update
• Monoclonal Antibody update
Recordings will be available immediately:

NYSDOH COVID-19 Healthcare Provider website

In addition to YouTube, an on-demand version of our weekly sessions for healthcare providers in NYS is now available as a podcast – search NYSDOH
Disclaimer

• The situation is rapidly evolving, as is our understanding of this new virus.

• All of the information presented is based on our best knowledge as of today.
COVID-19 Global Update

Bryon Backenson
Acting Director
Division of Bureau of Communicable Diseases
### Situation Summary: COVID-19 Global, 2/7/2021


<table>
<thead>
<tr>
<th>Region</th>
<th>Confirmed Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td><strong>105,429,382</strong></td>
<td><strong>2,302,614</strong></td>
</tr>
<tr>
<td>Western Pacific</td>
<td>1,481,789</td>
<td>25,885</td>
</tr>
<tr>
<td>Europe</td>
<td>35,515,952</td>
<td>781,242</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>13,033,797</td>
<td>200,267</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>5,828,565</td>
<td>136,950</td>
</tr>
<tr>
<td>Africa</td>
<td>2,655,316</td>
<td>65,736</td>
</tr>
<tr>
<td>Americas</td>
<td>46,913,218</td>
<td>1,092,521</td>
</tr>
</tbody>
</table>
Situation Summary: COVID-19 Global, 2/7/2021
www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

Figure 1: COVID-19 cases reported weekly by WHO Region, and global deaths, as of 7 February 2021**
Figure 2. COVID-19 cases per 100,000 population reported in the last seven days by countries, territories and areas, 1 February through 7 February 2021**
Situation Summary: COVID-19 Global, 12/15/2020
www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
CDC COVID Data Tracker (Feb 10, 2021)

Rate down from 74.8/100K 3 weeks ago

Situation Summary: COVID-19 U.S. (Feb 4, 2021)

Daily Trends in Number of COVID-19 Cases in the United States Reported to CDC
NYSDOH COVID-19 Tracker (Feb 4, 2021)

Found at: NYSDOH COVID-19 website

<table>
<thead>
<tr>
<th></th>
<th>Total Persons Tested</th>
<th>Total Tested Positive</th>
<th>% Positive Results</th>
<th>New Positives Today</th>
<th>Persons Tested Today</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Total</td>
<td>34,026,048</td>
<td>1,494,187</td>
<td>4.4%</td>
<td>7,101</td>
<td>176,750</td>
</tr>
<tr>
<td>ALL NYC</td>
<td>14,580,216</td>
<td>640,017</td>
<td>4.4%</td>
<td>3,318</td>
<td>71,336</td>
</tr>
</tbody>
</table>
| NYS Excluding NYC    | 19,445,832           | 854,170               | 4.4%               | 3,783               | 105,414             

% Positive Results Over Time - All Regions

Testing data as of: 2/9/2021
Testing data last updated on: 2/10/2021
COVID-19 Variants Update
COVID-19 Variants Update

SARS CoV-2

Mutation on the spike

SARS CoV-2 Variant

Better fit
Currently 3 main variants of public health interest:

UK variant: B.1.1.7

- 86 countries, 34 US states (932 detections), 61 detections in NY
- Increased transmissibility (36-75%), mixed evidence on increased severity, slight reduction in neutralization capacity
- No significant impact on Moderna, Pfizer, AstraZeneca vaccines
Figure 4: Weekly COVID-19 cases per 1 million population in the United Kingdom, as of 7 February 2021

- Cases
- Deaths
Currently 3 main variants of interest:

South African variant: B.1.351

- 44 countries, 3 US states (MD-6, SC-2, VA-1), none detected in NY
- Increased transmissibility (approx. 1.5x), no impact on severity reported, decrease in neutralization capacity—potential risk of reinfection
- Reduction of neutralization in neutralizing activity of Moderna, Pfizer vaccines, but practical impact unknown; lower vaccine efficacy in Novavax and J&J vaccines compared to other regions; minimal efficacy of AstraZeneca vaccine
Currently 3 main variants of interest:

Brazil variant: P.1

- 15 countries, 2 US states (MN-2, OK-1), none detected in NY
- Suggested increase in transmissibility, no evidence on increased severity, reduction in neutralization capacity still being determined
- Impacts on vaccine protection still being evaluated
COVID-19 Update

Jessica Kumar MPH, DO
Medical Director
Division of Bureau of Communicable Diseases
Multi-System Inflammatory Syndrome in Children and Adults MIS-C/A Updates

Updates on Children and Young Adults from ACIP
Increase in MIS-C

- As of 1/25/2021, there were 349 COVID cases investigated for MIS-C
- Between 1/13 and 2/9, more than 30 cases reported
- Concentrated in the Metropolitan Area region of NY, outside of NYC
Number of Cases of Pediatric Multisystem Inflammatory Syndrome Being Investigated and Reported through HERDS by Hospital Admission Date
HERDS data as of 02/08/2021
Number of Cases of Pediatric Multisystem Inflammatory Syndrome Being Investigated and Reported through HERDS by Hospital Admission Date
HERDS data as of 02/08/2021
Number of Cases of Pediatric Multisystem Inflammatory Syndrome Being Investigated and Reported through HERDS by Hospital Admission Date
HERDS data as of 02/08/2021
MIS-C NYS

**MIS-C New York State** Criteria (which differs from the [CDC](https://www.cdc.gov) definition)

**Clinical Criteria:** An individual aged < 21 years with:

- A minimum one-day history of subjective **OR** objective fever (≥ 100.4° F/38° C); **AND**
- Hospitalization; **AND**
- Either:
  - **One or more** of the following:
    - Hypotension or shock (cardiogenic or vasogenic)
    - Features of severe cardiac illness including but not limited to myocarditis, pericarditis, or valvulitis, significantly elevated troponin/pro-BNP, or coronary artery abnormalities
    - Other severe end-organ involvement including but not limited to neurological or renal disease (excluding severe respiratory disease alone)
  - OR
  - **Two or more** of the following:
    - Maculopapular rash
    - Bilateral non-purulent conjunctivitis
    - Mucocutaneous inflammatory signs (mouth, hands, or feet)
    - Acute gastrointestinal symptoms (diarrhea, vomiting, or abdominal pain);
  - **AND**

- The absence of a more likely diagnosis of the illness, e.g., bacterial sepsis or other viral infection.

2/11/21
General Laboratory Criteria: Two or more of the following markers of inflammation:
  • Neutrophilia, lymphopenia, thrombocytopenia, hypoalbuminemia, elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, D-Dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), OR elevated procalcitonin

Virologic Laboratory Criteria: One of the following SARS-CoV-2 laboratory results:
  • Detection of SARS-CoV-2 RNA in a clinical specimen using a molecular amplification detection test (e.g., RT-PCR) (or detection of SARS-CoV-2 antigen in a clinical specimen), at the time of presentation with this clinical picture or within the prior 4 weeks.
  • Detection of SARS-CoV-2 antibody in serum, plasma, or whole blood indicative of a new or recent infection.

Epidemiologic Criteria:
One or more of the following exposures in the 6 weeks prior to the onset of symptoms:
  • Close contact with an individual with laboratory-confirmed SARS-CoV-2 infection
  • Close contact with an individual with illness clinically compatible with COVID-19 disease who had close contact with an individual with laboratory-confirmed SARS-CoV-2 infection
  • Travel to or residence in an area with sustained, ongoing community transmission of SARS-CoV-2
## Vaccine clinical development: Children

<table>
<thead>
<tr>
<th>Platform/Design</th>
<th>mRNA: encodes stabilized spike; lipid NP</th>
<th>mRNA: encodes 2P-stabilized spike; lipid NP</th>
<th>Replication incompetent Ad26: stabilized spike</th>
<th>Replication incompetent ChAdOx1 chimp Ad; wild type spike</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose/ Schedule Adults</td>
<td>IM 2 doses X 30 µg 21 days apart</td>
<td>IM 2 doses 100 µg 28 days apart</td>
<td>IM 1 dose at $5 \times 10^{10}$ vp (also testing 2 doses (0, 56 days))</td>
<td>IM 2 doses at $5 \times 10^{10}$ vp, (0, 28 days)</td>
</tr>
<tr>
<td>Current Status</td>
<td>EUA ages 16 and up</td>
<td>EUA ages 18 and up</td>
<td>Phase 3 adults</td>
<td>Phase 3 adults</td>
</tr>
<tr>
<td>Adolescents</td>
<td>Fully enrolled</td>
<td>TeenCOVE</td>
<td>Start 4-6wks after results from adult trials</td>
<td>Begin Early 2021</td>
</tr>
<tr>
<td>Younger Children</td>
<td>Planning early 2021</td>
<td>Planning early 2021</td>
<td>Planning early 2021</td>
<td>Planning early 2021</td>
</tr>
<tr>
<td>Comments</td>
<td></td>
<td></td>
<td>Platform used widely in teens, infants, children</td>
<td></td>
</tr>
</tbody>
</table>

Others supported by USG: Novavax (Ph3 enrolling), Sanofi
MIS-A in Adults

• Since June 2020, there have been several reports of a similar multisystem inflammatory syndrome in adults (MIS-A)

• Like children, adults who have been infected with the virus that causes COVID-19 can develop symptoms of MIS-A days to weeks after getting sick.
  – Fever
  – Low blood pressure
  – Abdominal (gut) pain
  – Vomiting
  – Diarrhea
  – Neck pain
  – Rash
  – Chest tightness/pain
  – Feeling very tired

MMWR MIS-A in Adults published in Oct 2019
COVID-19 “Long Haulers”
Long-Term Effects of COVID

- Constellation of persistent symptoms and/or organ dysfunction after acute COVID-19
- CDC Late sequelae ~ 4 wks after initial infection
- NIH Clinical guidance for persistent symptoms
- NIH clinical critical care guidance

Clinical Trials
- Longitudinal Study of late sequelae and immunity
- California Study (UCSF)

2/11/2021
COVID-19 Re-opening: Indoor dining
Indoor Dining

- New York City Restaurants can now open on Lunar New Year Day, Feb 12
- Reopen at 25 percent capacity
- Restaurant workers were made eligible for vaccination the first week of Feb, along with taxi drivers and developmentally disabled communities
- CDC reopening guidance
- Going out to eat is associated with increased risk of coronavirus transmission
- Superspreader events and superspreader destinations (study)
- Relatively high density, how long patrons linger and go without masks, and, in many cases, poor ventilation
COVID-19 Vaccine Eligibility
Eligibility: Beginning February 15, 2021

Adult New Yorkers of any age with the following conditions qualify for the vaccine:

- Cancer (current or in remission, including 9/11-related cancers)
- Chronic kidney disease
- Pulmonary Disease, including but not limited to, COPD (chronic obstructive pulmonary disease), asthma (moderate-to-severe), pulmonary fibrosis, cystic fibrosis, and 9/11 related pulmonary diseases
- Intellectual and Developmental Disabilities including Down Syndrome
- Heart conditions, including but not limited to heart failure, coronary artery disease, cardiomyopathies, or hypertension (high blood pressure)
- Immunocompromised state (weakened immune system) including but not limited to solid organ transplant or from blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, use of other immune weakening medicines, or other causes
- Severe Obesity (BMI 40 kg/m2), Obesity (body mass index [BMI] of 30 kg/m2 or higher but < 40 kg/m2)
- Pregnancy
- Sickle cell disease or Thalassemia
- Type 1 or 2 diabetes mellitus
- Cerebrovascular disease (affects blood vessels and blood supply to the brain)
- Neurologic conditions including but not limited to Alzheimer's Disease or dementia
- Liver disease

The list is subject to change as additional scientific evidence is published and as New York State obtains and analyzes additional state-specific data.
Where can I go to be vaccinated?

Any individual who is eligible to be vaccinated may schedule an appointment to be vaccinated at any of the following locations that have vaccine supply:

- State-operated PODs (Point of Dispensing sites)
- Local Health Department PODs, conducted either by county health departments or by the New York City Department of Health and Mental Hygiene (NYCDOHMH)
- Hospitals
- Federally Qualified Health Centers (FQHCs)
- Urgent Care Centers

COVID Vaccine Locations

Immunization Screening and Consent Form

Screening Checklist for COVID Vaccine

Individuals ages 65 yrs and older may schedule an appointment to be vaccinated at any of the locations listed above, as well at pharmacy locations and physician network and practice group sites that have vaccine supply.

Only individuals 65+ can be vaccinated at pharmacy sites at this time.

All other eligible individuals should contact other enrolled providers to schedule vaccination.
New York State COVID-19 Vaccination Hotline at 1-833-NYS-4-VAX (1-833-697-4829)
COVID-19 Vaccine Updates
COVID-19 Infection After the First Dose

- Treated with monoclonal antibodies or convalescent serum: Delay second dose until 90 days after antibody treatment
- No antibody treatment, recovered and isolation completed before due for second dose: Give second dose on time
- Recovered but still in isolation when second dose is due: Delay second dose until after isolation is complete
- Isolation complete but still feeling ill when second dose is due: Delay second dose until recovered/not acutely ill
COVID-19 Infection After the First Dose

• Treated with monoclonal antibodies or convalescent serum: Delay second dose until 90 days after antibody treatment
• No antibody treatment, recovered and isolation completed before due for second dose: Give second dose on time
• Recovered but still in isolation when second dose is due: Delay second dose until after isolation is complete
• Isolation complete but still feeling ill when second dose is due: Delay second dose until recovered/not acutely ill
CDC Clinical Considerations for Use of mRNA COVID-19 Vaccines in U.S.

- [https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html)
- Regularly updated as information on COVID-19 vaccines and the pandemic evolve
- Last updated January 21, 2021
- [ACIP vaccine resources](#)
Johnson & Johnson COVID-19 Vaccine JNJ-78436735

• On January 29, 2021, Johnson & Johnson announced that the Phase 3 clinical study of its COVID-19 vaccine met primary endpoints for vaccine efficacy and safety
• 1 dose of their vaccine was 66% effective overall in moderate to severe COVID-19, 28 days after vaccination and 85% effective in preventing severe disease
• Rate of serious adverse events was similar to those who received placebo (not vaccine); “generally well tolerated”
• Johnson & Johnson plans to file a request for Emergency Use Authorization with the FDA in February 4th 2021

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

• Vaccine candidate 72% effective in the US and 66% effective overall at preventing moderate to severe COVID-19, 28 days after vaccination
• 85% effective overall in preventing severe disease and demonstrated complete protection against COVID-19 related hospitalization and death as of day 28
• Protection against severe disease across geographies, ages, and multiple virus variants, including the SARS-CoV-2 variant from the B.1.351 Lineage observed in South Africa
• Single-shot compatible with standard vaccine distribution channels provides important tool in pandemic setting
AstraZeneca COVID-19 Vaccine (AZD1222)

Adenovirus vector vaccines

Human adenovirus 26 (Ad.26) vector
- Nonreplicating
- Used in other vaccines (Ebola vaccine)
- Ad.26 Ebola vaccine used in broad populations, including pregnant women and children
- Previous exposure to the vector could reduce effectiveness

Chimpanzee adenovirus vector
- Nonreplicating
- Chimpanzee adenovirus vector circumvents preexisting immunity to human adenovirus
AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University and AstraZeneca

- AZD1222 induces robust immune responses against the SARS-CoV-2 S protein
- Spike Antibodies increased after a second dose comparable to convalescent sera
- Neutralizing Antibodies titers observed in all participants following 2nd dose
- Strong Th-1 biased CD4+ T Cell response observed
- US Phase III study ongoing with 32,459 participants enrolled with co-morbidities, older adults and diverse backgrounds
- 26,327 received second dose by Jan 21, 2021
- Efficacy and safety were demonstrated in four Phase I-III studies in UK, Brazil and South Africa
- AZD1222 has the potential to address the SARS-CoV-2 pandemic and has been authorized in 18 countries (under emergency use or full approval as of January 25, 2021)

[WHO recommendation for AZD1222](#)
# OWS Supported SARS-CoV-2 Vaccines

<table>
<thead>
<tr>
<th>Platform/Design</th>
<th>mRNA: encodes 2P-stabilized Spike, TM, FI</th>
<th>Replication Incompetent Ad26; Stab. Spike; ΔF; TM</th>
<th>Replication incompetent ChAdOx1 wild type Spike; ΔF; TM</th>
<th>Baculovirus Expressed trimeric Stabilized Spike, ΔF; TM</th>
<th>Baculovirus Expressed trimeric Stabilized Spike, ΔF; TM + AS03</th>
<th>mRNA: encodes stabilized SARS-CoV-2 Spike</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose/Schedule</td>
<td>2 doses 100 µg (0.28 days)</td>
<td>1 dose at 5 × 10^{10} vp, (0-28 days)</td>
<td>2 doses at 5 µg + Matrix M (0.21 days)</td>
<td>5/15 µg + AS03 (0.21 days)</td>
<td>2 doses X 30 µg (0, 21 days)</td>
<td></td>
</tr>
<tr>
<td>Current Status</td>
<td>Phase 3 US (start date July 27th)</td>
<td>Phase 3 international (includes US)</td>
<td>Phase 3 International</td>
<td>Phase 2 International</td>
<td>Phase 1</td>
<td>Phase 2-3 international (start date July 27th)</td>
</tr>
<tr>
<td>Phase 3 Est. Start Date</td>
<td>Finished recruiting</td>
<td>Ongoing</td>
<td>Ongoing</td>
<td>November 2020</td>
<td>December 2020</td>
<td>Ongoing (close to completing recruitment)</td>
</tr>
<tr>
<td>DART</td>
<td>Ongoing-Report expected Q1 2021</td>
<td>Ongoing-Report expected Q1 2021</td>
<td>Expected to start Q4 2020</td>
<td>Ongoing-Report expected Q1 2021</td>
<td>Expected to start Q4 2020</td>
<td>Will complete DART study, Date unknown</td>
</tr>
<tr>
<td>Pregnancy Exposure</td>
<td>NO; Platform has been tested in adults</td>
<td>Yes, Ad26+ Ebola (1000 patients) Current pregnancy trials ongoing</td>
<td>NO; Platform has been tested in adults</td>
<td>Baculovirus Expression YES; Adjuvant has been tested in adults</td>
<td>Baculovirus expression YES; Adjuvant in commercial vaccine (Pandemrix, Arepanrix)</td>
<td>NO</td>
</tr>
<tr>
<td>Comments</td>
<td>DART with previous formulations; no concerns</td>
<td>Recruiting lactating women in their Phase 3</td>
<td>Extensive experience with pregnancy trials (RSV+Alum)</td>
<td>GSK conducting pregnancy trials (Phase 2) for RSV vaccine</td>
<td>Pfizer conducting pregnancy trials (Phase 3) for RSV vaccine</td>
<td></td>
</tr>
</tbody>
</table>
COVID-19 Vaccine Safety Update

Henry (Hank) Bernstein, DO, MHCM, FAAP
Professor of Pediatrics
Zucker School of Medicine
Cohen Children’s Medical Center
COVID-19 Vaccine Safety Update

Henry (Hank) Bernstein, DO, MHCM, FAAP
Professor of Pediatrics
Zucker School of Medicine
at Hofstra/Northwell
Other COVID-19 Updates

Marcus Friedrich, MD, MHCM, FACP
Chief Medical Officer
Office of Quality and Patient Safety
Monoclonal Antibody update

- FDA authorizes new monoclonal antibodies for treatment of COVID-19
- Bamlanivimab and Etesevimab
- Administered together for the treatment of **mild to moderate** COVID-19 in **adults and pediatric** patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.
COVID-19
Resources
What is the Provider Compilation Document?

- Contains links to the most recently available COVID-19 guidance for healthcare providers.
- Includes links and guidance for:
  - Vaccinations, testing, quarantine, infection control and other relevant information for outpatient healthcare providers.
- Updated weekly or as new guidance is released.
# NYSDOH COVID-19 Healthcare Provider Compilation

**As of January 5, 2021, 9:00 AM**

*The information in this compilation is current only as of the above date and time.*

**Purpose:** The purpose of this publication is to provide healthcare providers in New York State with a consolidated reference document of guidance released by the New York State Department of Health (NYSDOH) related to the COVID-19 pandemic response. This document displays hyperlinks to the current guidance documents. Additional COVID-19 resources may be found on the NYSDOH [Information for Healthcare Providers](https://www.health.ny.gov/disease/coronavirus/covid19/index.shtml) webpage. Recordings of COVID-19 [Weekly Healthcare Provider Updates](https://www.health.ny.gov/disease/coronavirus/covid19/index.shtml) are also available on the NYSDOH webpage.

## COVID-19 Vaccine Information for Providers

### Link to Guidance

**NYSDOH COVID-19 Vaccine Webpage**

- How to Order COVID-19 Vaccine
- Documents and Guidance on Administering the COVID-19 Vaccine and Vaccine Prioritization
- Provider Training

**Determine Eligibility for a Vaccine and Find a Local Vaccination Site to Make an Appointment**

## Testing and Specimen Collection

### Link to Guidance

**NYSDOH COVID-19 Testing Webpage**

- Antigen Testing
- Antibody Testing
- Molecular Testing
- Protocols for Drive-Through Testing

**DOH Wadsworth Center Coronavirus Testing Guidance Webpage**

- Specimen Collection, Handling and Transport
- Guidance on Pooling
- Test Results Reporting
- Infectious Disease Requisition
COVID-19 Healthcare Provider Compilation

- Link on NYSDOH web page: https://coronavirus.health.ny.gov/information-healthcare-providers

Information for Healthcare Providers

COVID-19 INFORMATION FOR PROVIDERS

Providing up-to-date information about the COVID-19 outbreak for NYS healthcare providers, including:

- COVID-19 Vaccine Information for Providers
- Weekly health care provider updates
- COVID-19 webinars, health advisories, printable materials and guidance
- COVID-19 Testing Information
- Joining the NYS health care provider reserve workforce
- Creating a Health Commerce Account

For questions, contact covidproviderinfo@health.ny.gov
NY State DOH COVID-19 Hotline

Call the Hotline: 1-888-364-3065 or Ask a Question

New Yorkers Can Now Report Vaccine-Related Fraud by Calling 833-VAX-SCAM (833-829-7226) or Emailing STOPVAXFRAUD@health.ny.gov
COVID Alert NY is a voluntary, anonymous, exposure-notification smartphone app.

You will get an alert if you were in close contact with someone who tests positive for COVID-19.

Knowing about a potential exposure allows you to self-quarantine immediately, get tested and reduce the potential exposure risk to your family, friends, neighbors, co-workers and others.

The more people who download COVID Alert NY, the more effective it will be.

Help protect your community while maintaining your privacy.

The free mobile apps—available to anyone 18 or older who lives, works, or attends college in New York or New Jersey—are available for download from the Google Play Store or Apple App Store. COVID Alert NY is available in English, Spanish, Chinese, Bengali, Korean, Russian and Haitian Creole.

Download the free app to your smartphone to receive an alert if you have been in close contact with someone who has tested positive for COVID-19.
Healthcare Provider Well-Being
Healthcare Provider/Physician Wellness

Supporting Healthcare Provider Well-Being in COVID & Beyond

July 9, 2020

Howard Zucker, MD, JD
Commissioner of Health, New York State

https://www.youtube.com/watch?v=B9PRLV-_XQE
Mental Health Resources

• **NYS Mental Health Helpline**
  1-844-863-9314

• The helpline is staffed by specially trained volunteers, including mental health professionals, who have received training in crisis counseling related to mental health consequences of infectious disease outbreaks, typical stress reactions, anxiety management, coping skills, and telephonic counseling.
Healthcare Provider/Physician Wellness

- The state is partnering with the Kate Spade New York Foundation and Crisis Text Line to provide a 24/7 emotional support service for frontline healthcare workers
  - Text NYFRONTLINE to 741-741 to access these emotional support services
- New York State-regulated health insurers will be required to waive cost-sharing, including deductibles, copayments and coinsurance, for in-network mental health services for frontline essential workers during COVID-19
Mental Health Resources

COVID-19 Resources

The COVID-19 pandemic has left many New Yorkers feeling anxious and stressed.

Learn more about:
- The COVID-19 Vaccine
- Managing anxiety in difficult times
- Coronavirus-related guidance for healthcare providers
- How you can help

VACCINATION INFORMATION

New York State COVID-19 Vaccine webpage
Learn more about the State’s distribution plan and if you’re eligible for the vaccine.

OMH COVID-19 Vaccine Fact Sheet
Get answers to common questions about the COVID-19 Vaccine.

PUBLIC RESOURCES

NY Project Hope Emotional Support Helpline: 1-844-863-9314 *
New York has a free, confidential helpline as part of the FEMA response to COVID-19. Call 1-844-863-9314 or visit nypjho.org.

Tips for Mental Wellness
How to manage COVID-related stress and anxiety

Mental Health in the Next Phase of Coronavirus
A guide of coping tips and resources to help with the ongoing mental health impact of the pandemic.

Mental Health Resources During an Emergency
People often experience anxiety, fear, and helplessness during an emergency. Know the signs and get help.

https://omh.ny.gov/omhweb/covid-19-resources.html
Are you struggling with everyday life stressors? MSSNY’s P2P Supporters are here to help

Any physician, resident or medical student who wishes to relate to a peer supporter may contact the Medical Society of the State of New York in the following ways:

- Email: P2P@mssny.org
- Phone 1-844-P2P-PEER (1-844-727-7337)

Support, Empathy & Perspective
CDC COVID-19 Website

Additional COVID-19 Resources
NYS resources

- [https://forward.ny.gov/early-warning-monitoring-dashboard](https://forward.ny.gov/early-warning-monitoring-dashboard)
- Testing/tracing
- New infections/severity based on hospitalization
- Hospital capacity
Helpful Links

• **HERO Together: COVID vaccine effects study**
• **New York State** vaccine tracker
• **NY Times** vaccine tracker
Highlighted CDC resources

- **Update to COVID-19 clinical considerations**: [www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html](http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html)


- **Estimated Disease Burden of COVID-19**: estimates of COVID-19 infections, symptomatic illnesses, and hospitalizations using a statistical model to adjust for cases that national surveillance networks are unable to capture for a number of reasons.

- These estimates and methodology used to calculate them are published in *Clinical Infectious Diseases* and available [online](https://cid.oxfordjournals.org/content/early/2021/01/19/cid.3185). To learn more, please visit: [Estimated COVID-19 Burden](https://covid19.cdc.gov/covid19/burden/index.html)
CDC Upcoming Pending Topics

- **2/08/2021**: Tools for Essential Workers
- **2/22/2021**: Finding the Silver Lining: Advancing Smoke-Free Protections During the COVID-19 Pandemic
NYS Medicaid Telehealth Updates and Guidance

NYSDOH COVID-19 Guidance for Medicaid Providers website

- **Webinar**: New York State Medicaid Guidance Regarding Telehealth, Including Telephonic, Services During the COVID-19 Emergency - 5.5.2020
  - Slides (PDF)
  - Recording Coming Soon

- **Frequently Asked Questions (FAQs)** on Medicaid Telehealth Guidance during the Coronavirus Disease 2019 (COVID-19) State of Emergency - (Web) - (PDF) - Updated 5.1.2020
Telehealth Guidance

• American College of Physicians Telehealth Resource:
  www.acponline.org/practice-resources/business-resources/health-information-technology/telehealth

• CDC Outpatient and Ambulatory Care Setting Guidance:

• Medicaid:
  www.health.ny.gov/health_care/medicaid/program/update/2020/
NYSDOH COVID-19 Website

LAST UPDATED: JANUARY 13, 2021 AT 2:30 PM

What You Need to Know

- Visit ny.gov/vaccine to get the facts on the COVID-19 Vaccine in New York.
- The COVID-19 Emergency Eviction and Foreclosure Prevention Act places a moratorium on residential evictions until May 1, 2021 for tenants who have endured COVID-related hardship.
- A new Micro-Cluster Strategy is addressing COVID-19 hot spots that have cropped up across the state.
  - Look up an address to see if falls into a Red, Orange, or Yellow Zone
  - See the restrictions that correspond to each color-coded level of cluster zone
- Indoor and outdoor gatherings at private residences are limited to no more than 10 people.
- Read New York’s COVID-19 Winter Plan to mitigate the spread of the virus and bolster New York’s hospital’s preparedness.
- New travel guidelines are in effect that allow out-of-state travelers to “test out” of the mandatory 10-day quarantine.
- To report violations of health and safety restrictions and requirements for businesses, gatherings and individuals, please choose the appropriate link below:
  - File a complaint about a business, location or incident in your community.
  - File a complaint against your employer or place of work.
- Health care workers can text NYFRONTLINE to 741-741 to access 24/7 emotional support services. Any New Yorker can call the COVID-19 Emotional Support Hotline at 1-844-863-9314 for mental health counseling.

https://coronavirus.health.ny.gov/home
# NYSDOH COVID-19 Website

PROTECTING THE PUBLIC HEALTH OF ALL NEW YORKERS

<table>
<thead>
<tr>
<th>Schools</th>
<th>Mental Health Resources</th>
<th>Mandatory and Precautionary Quarantine</th>
<th>Seasonal Celebrations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare Providers</td>
<td>Long-Term Care Facilities</td>
<td>Childcare Providers</td>
<td>Childhood Inflammatory Disease Related to COVID-19</td>
</tr>
<tr>
<td>Movie Theaters</td>
<td>Ski Facilities</td>
<td>Pregnancy Guidelines</td>
<td>Donate Blood</td>
</tr>
<tr>
<td>Employees &amp; Employers</td>
<td>Insurance</td>
<td>Cyber Security</td>
<td>Price Gouging</td>
</tr>
</tbody>
</table>

https://coronavirus.health.ny.gov/home
NYSDOH COVID-19 Testing Website

https://coronavirus.health.ny.gov/covid-19-testing
Mirror Clings

To order mirror clings for public use email the NYSDOH:

bmcc@health.ny.gov
QUESTIONS?

TO NYS HEALTHCARE PROVIDERS

THANK YOU!